On the one hand, according to previous studies involving osteoporotic men (20), patients with Klinefelter syndrome (KS) (3, 21), and those on androgen deprivation therapy for prostate cancer (22), FSH appears to have a detrimental effect on the male bone. Here, BRD2 is linked to prostate cancer.